chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Polydipsia, Thirst, Urine output decreased
Clinical narrative: On April 24th, 5 days after the vaccine, "I" started "my" period. "I" am on BC that makes "me" not have "my" period. "I" am still taking "my" pill as normal, but "I" am experiencing a heavy flow and painful cramps.; On April 24th, 5 days after the vaccine, "I" started "my" period. "I" am on BC that makes "me" not have "my" period. "I" am still taking "my" pill as normal, but "I" am experiencing a heavy flow and painful cramps.; "I" was drinking so much and hardly peeing at all.; "I" was drinking so much and hardly peeing at all.; The night after getting the vaccine and carrying over through the next day, was excessively thirsty.  "I" was drinking so much and hardly peeing at all.; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm right on 19Apr2021 at 13:30(at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient's medical history included birth control. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. The concomitant medications included bupropion hydrochloride (WELLBUTRIN XL) for unspecified indication and norethisterone (NORETHINDRONE) for birth control, all from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the right arm on 26Mar2021 at 14:00(at the age of 33-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, the night after getting the vaccine and carrying over through the next day, the patient was excessively thirsty and was drinking so much and hardly peed at all. On 24Apr2021 at 07:00, 5 days after the vaccine the patient's period started. She was on her birth control (BC) that made her not had her period. She was taking her pill as normal at the time of report, but experienced a heavy flow and painful cramps. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events excessively thirsty, drinking so much, hardly peed, a heavy flow and painful cramps were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vomiting
Clinical narrative: Feverish; Vomiting; Felt sore; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 03Apr2021 at 12:00 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Concomitant medications included ethinylestradiol/ levonorgestrel (AVIANE) pills taken for birth control from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 04Apr2021 at 00:00, 12 hours after the vaccination, the patient started to feel feverish and then started vomiting. The patient vomited every 10 to 15 minutes for the next 5 hours and could not keep down even water. The patient then felt sore and feverish for the next 15 hours. It was reported that the patient never heard or read of anyone with extensive vomiting as a symptom. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events feverish, vomiting and felt sore was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Inappropriate schedule of product administration, Nausea, Pain
Clinical narrative: Fever; Body chills; Body aches; Headache; Nausea; Dose 1 date: 03Mar2021, Dose 2 date: 24Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the right arm on 24Apr2021 at 12:15 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 03Mar2021 at 16:45 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021 at 05:00, the next day, the patient experienced fever, body chills, body aches, headache, and nausea which lasted two days after shot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, body chills, body aches, headache and nausea was recovered on 26Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; Body chills; Body aches; Headache; Nausea; Dose 1 date: 03Mar2021, Dose 2 date: 24Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the right arm on 24Apr2021 at 12:15 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 03Mar2021 at 16:45 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021 at 05:00, the next day, the patient experienced fever, body chills, body aches, headache, and nausea which lasted two days after shot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, body chills, body aches, headache and nausea was recovered on 26Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Nausea, Tremor, Vomiting
Clinical narrative: Nausea; Vomiting; Chills; Shaking; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 16:15 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Concomitant medications included zolpidem (MANUFACTURER UNKNOWN) and hydroxyzine (MANUFACTURER UNKNOWN); for unknown indication from an unknown date and unknown if ongoing. On 26Apr2021, the patient experienced, nausea, vomiting, chills and shaking. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, vomiting, chills and shaking was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia
Clinical narrative: Intense and Debilitating joint/muscle pain from head to toe.; Intense and Debilitating joint/muscle pain from head to toe.; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included naproxen (MANUFACTURER UNKNOWN) and ethinylestradiol, norethisterone (NORTREL); both for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation and received cefprozil (CEFZIL) for unknown indication on unknown date and experienced drug allergy.  On 26Apr2021 at 03:30, the patient experienced intense and debilitating joint/muscle pain from head to toe. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown, if the patient received any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events intense and debilitating joint/muscle pain from head to toe was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, Diarrhoea, Vomiting
Clinical narrative: Sever stomach pains resulting in 24 hours of diarrhea and vomiting; 24 hours of diarrhea and vomiting.; 24 hours of diarrhea and vomiting.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 21Apr2021 at 07:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 24Apr2021 at 22:00, the patient experienced sever stomach pains resulting in 24 hours of diarrhea and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of the events sever stomach pains resulting in 24 hours of diarrhea and vomiting was not recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Muscle spasms, Vomiting
Clinical narrative: Vomiting; Extreme muscle cramps; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 21Apr2021 at 15:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had a unspecified medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified concomitant medications. On 22Apr2021, the patient experienced vomiting, extreme muscle cramps and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vomiting, extreme muscle cramps and extreme fatigue was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: My lymph nodes in my neck and around my collarbone are swollen and painful; My lymph nodes in my neck and around my collarbone are swollen and painful; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on an unknown date in Apr2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to melons, and berries. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive concomitant medications. The patient did not receive any other vaccine within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 01Apr2021 at 13:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient previously received  cefaclor (CECLOR) and experienced drug allergy. On 23Apr2021 at 06:00, the patients lymph nodes in neck and around collarbone were swollen and painful. The day of report was day 4 since the second shot and she had noticed only a one big swollen lymph node on left collarbone but as the days went by, patient was finding more. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lymph nodes in neck and around collarbone were swollen and painful were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Nausea, Pain
Clinical narrative: 101 degree fever; Chills; Vomiting; Nausea; Headache; Aches; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm right on 21Apr2021 at 13:45 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included algae oil pills (MANUFACTURER UNKNOWN) and turmeric (MANUFACTURER UNKNOWN) from unknown dates and unknown if ongoing for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8489) via an unspecified route of administration in the arm left on 31Mar2021 at 14:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 08:30, the patient experienced 101 degree fever, aches, and chills after 12 hours for 24 hours duration followed by nausea, vomiting and headache for an additional 48 hours. On 22Apr2021 at 08:30, the patient underwent body temperature test and the result was 101 degree with unspecified unites. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events 101-degree fever, chills and aches were recovered on 23Apr2021. The clinical outcome of the events vomiting, nausea and headache were recovered on 25Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: 101 degree fever; Chills; Vomiting; Nausea; Headache; Aches; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the arm right on 21Apr2021 at 13:45 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included algae oil pills (MANUFACTURER UNKNOWN) and turmeric (MANUFACTURER UNKNOWN) from unknown dates and unknown if ongoing for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8489) via an unspecified route of administration in the arm left on 31Mar2021 at 14:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 08:30, the patient experienced 101 degree fever, aches, and chills after 12 hours for 24 hours duration followed by nausea, vomiting and headache for an additional 48 hours. On 22Apr2021 at 08:30, the patient underwent body temperature test and the result was 101 degree with unspecified unites. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events 101-degree fever, chills and aches were recovered on 23Apr2021. The clinical outcome of the events vomiting, nausea and headache were recovered on 25Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dehydration, Dysgeusia, Headache, Nausea
Clinical narrative: Chills; Low-grade fever; Major headache; Nausea; Dehydration; Adverse taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: GW0172) via an unspecified route of administration in the arm right on 24Apr2021 at 10:45 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram 20mg (MANUFACTURER UNKNOWN), ibuprofen (MANUFACTURER UNKNOWN) and rizatriptan 10 mg (MANUFACTURER UNKNOWN), all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the arm right on 03Apr2021 at 10:45 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, the patient experienced chills, low-grade fever, major headache, nausea, dehydration and adverse taste in mouth. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, low-grade fever, major headache, nausea, dehydration and adverse taste in mouth was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Chills; Low-grade fever; Major headache; Nausea; Dehydration; Adverse taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: GW0172) via an unspecified route of administration in the arm right on 24Apr2021 at 10:45 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram 20mg (MANUFACTURER UNKNOWN), ibuprofen (MANUFACTURER UNKNOWN) and rizatriptan 10 mg (MANUFACTURER UNKNOWN), all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the arm right on 03Apr2021 at 10:45 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, the patient experienced chills, low-grade fever, major headache, nausea, dehydration and adverse taste in mouth. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, low-grade fever, major headache, nausea, dehydration and adverse taste in mouth was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Left arm sore for 3 days; Very tired; This is a spontaneous report from a non-contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 14:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications within two weeks of vaccination. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient did not receive any other vaccine within four weeks prior to the vaccination. On 19Apr2021, the patient experienced left arm sore for 3 days and felt very tired for 2 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very tired was resolved on 21Apr2021, after the duration of 2 days and of left arm sore was resolved on 22Apr2021, after the duration of 3 days.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Disturbance in attention, Fatigue, Lymphadenopathy
Clinical narrative: a lump in my lymph node on my right collarbone; cough; fatigue; At times I also have trouble focusing; This is a spontaneous report from a contactable consumer (patient). This 58-year-old male patient received dose 2 of BNT162B2 (lot number EP6955) via an unspecified route of administration on 24Mar2021 at 09:30 (at the age of 58-years-old) as a single dose in the right arm for COVID-19 immunization. Medical history included gout. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Concomitant medications included allopurinol 300 mg from an unknown date for an unknown indication. The patient did not have any known allergies. The patient previously received dose 1 of BNT162B2 (lot number EN6206) on 03Mar2021 at 09:30 as a single dose in the right arm for COVID-19 immunization. On 25Mar2021 at 07:00 the patient developed a lump in his lymph node on his right collarbone. It had reduced in size but was still present. He still had a cough and fatigue. At times he had trouble focusing. The patient visited a doctor or other healthcare professional office/clinic as a result of the events. The patient received treatment with a steroid shot antibiotic shot, and cough medicine. The outcome of lump in his lymph node was recovering. The outcomes of cough, fatigue, and trouble focusing were not recovered. It was also reported that since the vaccination the patient had not been tested for COVID-19.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Urticaria
Clinical narrative: Broke out in hives; Itchy hands and feet; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the left arm on 31Mar2021 at 11:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included low thyroid, glaucoma and hypertension. The patient had unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC), losartan (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID) and ergocalciferol (VIT D) and unspecified daily multiple; all from unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via an unspecified route of administration in the left arm on 10Mar2021 at 11:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. On 09Apr2021 at 07:00, the patient broke out in hives, itchy hands and feet. The event resulted in emergency room or department or urgent care. Therapeutic measures were taken as a result of the adverse events and included treatment with PREDNISONE, famotidine (PEPCID), cetirizine hydrochloride (ZYRTEC) and diphenhydramine hydrochloride (BENADRYL); all from an unknown date and unknown if ongoing. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events broke out in hives, itchy hands and feet were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lymphadenopathy
Clinical narrative: Swelling in the lymph nodes (lymphadenopathy); Very bad headache (headache); This is a spontaneous report from a non-contactable pharmacist. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via intramuscular route of administration on 09Apr2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. It was unknown if the patient had any relevant medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. It was unknown if the patient received any concomitant mediations. On 10Apr2021, the patient developed swelling in the lymph nodes (lymphadenopathy) and 'very bad headache' (headache) shortly after the 1st dose of the COVID-19 vaccine. Both events lasted for about a week and a half and have resolved. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling in the lymph nodes (lymphadenopathy) and very bad headache (headache) was resolved on an unspecified date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Late/missed menstrual cycle; This is a spontaneous report from a contactable healthcare professional, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via intramuscular route of administration in the left arm on 09Feb2021 at 15:30 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and factor 5 heterozygous.  Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included beclometasone dipropionate (QVAR), pantoprazole (MANUFACTURER UNKNOWN), cannabidiol (CBD OIL) and mentha x piperita oil (PEPPERMINT OIL)(IB GARD); all for unknown indication from unknown start date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL0142) via intramuscular route of administration in the left arm on 19Jan2021 at 15:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient previously took cefaclor (CECLOR) and experienced drug allergy. On 12Feb2021 the patient experienced late/missed menstrual cycle. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event late/missed menstrual cycle was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Arthralgia, Fatigue, Myalgia, Rash
Clinical narrative: Muscle soreness; Rash on fingers; Aches in both shoulder; Exhaustion; Intestinal distress; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the right arm on 01Mar2021 at 14:15 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes and pancreatic cancer. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included ezetimibe (MANUFACTURER UNKNOWN); taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9269) via an unspecified route of administration in the left arm on 29Jan2021 at 14:30 as a single dose for COVID-19 immunisation. On 08Mar2021, the patient experienced muscle soreness, rash on fingers, aches in both shoulder, exhaustion and intestinal distress. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event rash on fingers and included treatment with unspecified steroid and topical. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle soreness, rash on fingers, aches in both shoulder, exhaustion and intestinal distress were resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia, SARS-CoV-2 test, Tinnitus
Clinical narrative: Acute ringing in ears at an extremely high pitched level; It is constant and wakes me from sleep; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6202) via an unspecified route of administration in the left arm on 26Feb2021 at 16:30 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included systemic lupus erythematosis (reported as systemic lupus). The patient had no known allergies.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included methylprednisolone (MANUFACTURER UNKNOWN) for unknown indication, from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Feb2021 at 14:45 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the vaccination. On 15Mar2021 at 06:00, the patient experienced acute ringing in ears at an extremely high-pitched level.  It was constant and woke patient from sleep. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On 05Apr2021, the patient underwent Polymerase Chain Reaction (PCR) test for COVID- 19 via nasal swab and the result was negative. The clinical outcome of the events acute ringing in ears at an extremely high-pitched level; it was constant and woke patient from sleep were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Menstrual bleeding the day after the vaccine, the flow was heavy; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 06Apr2021 at 15:30 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had allergies to penicillin, peppers, birch and grass pollen. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications. On 07Apr2021 at 23:30, the patient experienced menstrual bleeding the day after vaccine, flow was heavy. The patient was in the middle of menstrual cycle and takes birth control (unknown medications). The patient had never experienced bleeding in the middle of menstrual cycle in the three years, the patient had been on birth control. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event menstrual bleeding the day after the vaccine, the flow was heavy was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Felt tired the day of and next two days after receiving vaccine; Got a headache the next 2 days after receiving vaccine; Pain on injection site; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration on an unknown date (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On an unknown date, the patient felt tired the day of and next two days after receiving vaccine, got a headache the next 2 days after receiving vaccine and also had pain on injection site. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events felt tired the day of and next two days after receiving vaccine, got a headache the next 2 days after receiving vaccine and also had pain on injection site was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Vomiting
Clinical narrative: On the following day after vaccination, Saturday April 24th, "I" began vomiting in the afternoon around 2pm and could not keep anything down. Thelast time "I" vomited was around midnight; Also during this time "I" had an excruciating headache. The headache continued throughout Sunday, April 25th; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 23Apr2021 at 08:30 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. On 24Apr2021 at 14:00, on the following day after vaccination in the afternoon, the patient experienced vomiting and could not keep anything down. The last time he vomited was around midnight and also during that time he had an excruciating headache where it was continued throughout Sunday, April 25th. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vomiting was recovered on an unknown date in Apr2021, while the clinical outcome of the event excruciating headache was recovering at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pyrexia, Vaccination site pain
Clinical narrative: "I" began having side effects that included headaches muscle pain fever and soreness of injection site.; "I" began having side effects that included headaches muscle pain fever and soreness of injection site.; "I" began having side effects that included headaches muscle pain fever and soreness of injection site.; "I" began having side effects that included headaches muscle pain fever and soreness of injection site.; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 24Apr2021 at 15:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The medical history included high blood pressure and asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. On 25Apr2021 at 14:00, the patient began having side effects that included headaches, muscle pain, fever and soreness of injection site. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headaches, muscle pain, fever and soreness of injection site were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: I was supposed to get my period the day of the vaccine. I am now 6 days late.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the arm left on 20Apr2021 at 10:30(at the age of 33-year-old) as a single dose for COVID-19 immunisation. Medical history included acne and attention deficit hyperactive disorder (ADHD). The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) and spironolactone (SPIRONOLACTON) all from unknown date for unknown indication and unknown if ongoing. On 20Apr2021 at 10:30, the patient experienced delayed period. The Patient reported that she was supposed to get her period on the day of the vaccination, but was 6 days late. The Patient had tested negative for pregnancy tests. There had been no changes in diet, exercise, weight, stress this month and  the patient had always exercised, managed weight and stress that month, and also her periods had always been extremely regular and had never missed a period or been late (with the exception of 2 pregnancies). The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested positive for COVID-19. The clinical outcome of the event, delayed period was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Nausea
Clinical narrative: Extremely lightheaded/dizzy/lightheadedness; Nauseas; Chilling/ chills; Started getting headache and was tired.; Started getting headache and was tired.; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 09:15 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history was reported that the only thing the patient could thought was she had a temporary crown dental appointment on Tuesday, 24Apr2021. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no any known allergies. Concomitant medications included amoxicillin (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Apr2021 at 09:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021, the patient had a normal routine after vaccination and started getting headache and was tired. The patient had no exertion on Saturday (24Apr2021) and worked on computer. On 25Apr2021, the patient went to work in yard (patient used to do every day) and within 30 minutes at 14:30, the patient experienced extremely lightheaded, dizzy, nauseas and started chilling. The patient slept all the night and woke up next morning (26Apr2021) with chills headache and light-headedness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, tired, extremely lightheaded/dizzy/lightheadedness, nauseas and chilling/chills was not resolved at the time of this report..  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.